Apalutamide

Contraindicated

Apalutamide Doravirine Pifeltro Reduced doravirine exposure, reduced efficacy of doravirine and an increased risk of doravirine resistance Details Apalutamide Fostemsavir Rukobia Reduced temsavir (the active moiety of fostemsavir) exposure and possible loss of virologic response Details Apalutamide Lenacapavir Injection Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Apalutamide Lenacapavir Oral Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Apalutamide Lurasidone Latuda Reduced lurasidone exposure Details Apalutamide Nifedipine Adalat® Reduced NIFEdipine exposure and reduced efficacy of NIFEdipine Details

Major

Apalutamide Acetaminophen And Codeine Capital® & Codeine Explained Reduced codeine and morphine exposure, reduced opioid efficacy and precipitation of opioid withdrawal Details Apalutamide Clindamycin ANTIROBE Explained Reduced CYP3A4 substrate exposure Details Apalutamide Omeprazole Gastrobim Explained Reduced CYP2C19/CYP3A4 substrate exposure Details Apalutamide Sertraline Explained Reduced CYP3A4 substrate exposure Details Apalutamide Buprenorphine Belbuca Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Apalutamide Relugolix Orgovyx Explained Reduced relugolix exposure and reduced efficacy of relugolix Details Apalutamide Colchicine Colcrys Explained Reduced P-gp/CYP3A4 substrate exposure Details Apalutamide Simvastatin Flolipid Explained Reduced simvastatin exposure Details Apalutamide Abemaciclib Verzenio Explained Reduced CYP3A4 substrate exposure Details Apalutamide Abrocitinib Cibinqo Explained Decreased abrocitinib and active metabolite exposure Details Apalutamide Acalabrutinib Calquence Reduced acalabrutinib exposure Details Apalutamide Aliskiren Tekturna Reduced P-gp substrates exposure Details Apalutamide Alpelisib Piqray Reduced alpelisib exposure and reduced efficacy of alpelisib Details Apalutamide Apixaban Eliquis Explained Reduced apixaban exposure, reduced efficacy of apixaban and an increased risk of stroke and other thromboembolic events Details Apalutamide Apremilast Otezla Reduced apremilast exposure and an reduced efficacy of apremilast Details Apalutamide Aripiprazole Injection Abilify Reduced ARIPiprazole exposure Details Apalutamide Asciminib Scemblix Reduced CYP3A4 substrate exposure Details Apalutamide Atogepant Qulipta Reduced atogepant exposure Details Apalutamide Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Apalutamide Avatrombopag Doptelet Reduced CYP3A4/CYP2C9 substrate exposure Details Apalutamide Belumosudil Rezurock Explained Reduced belumosudil exposure and reduced efficacy of belumosudil Details Apalutamide Betrixaban Bevyxxa® Decreased betrixaban exposure Details Apalutamide Atorvastatin Atorvaliq Reduced OATP1B1/CYP3A4 substrate exposure Details Apalutamide Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Apalutamide Abiraterone Abirtega Reduced abiraterone exposure and reduced efficacy of abiraterone Details Apalutamide Afatinib Gilotrif Decreased afatinib exposure Details Apalutamide Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Apalutamide Alfuzosin UroXatral Reduced CYP3A4 substrate exposure Details Apalutamide Amlodipine Amvaz® Reduced CYP3A4 substrate exposure Details Apalutamide Avanafil Stendra Reduced CYP3A4 substrate exposure Details Apalutamide Axitinib Inlyta Reduced OATP1B1/CYP3A4 substrate exposure Details Apalutamide Bedaquiline Sirturo Reduced bedaquiline exposure and reduced efficacy of bedaquiline Details Apalutamide Bortezomib Boruzu Reduced bortezomib exposure Details Apalutamide Bosutinib Bosulif Reduced CYP3A4 substrate exposure Details